Analytica (ASX: ALT) Receives $720k Placement Funds, Release PeriCoach V3 & Appoints New Director

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach System and AutoStart Infusion system has recently released its Quarterly Cashflow report for the period ending June 30, 2017.

KEY TAKEAWAYS:

• Appointment Dr Peter B.Corr director
• Release of PeriCoach vision 3 (V3) device
• PeriCoach structured exercise program released
• Cash balance as of 30^th June, $1,212k
• Share placement approved by shareholders in April for $720k
• Investigating AutoStart infusion system use-age for Home Based Hospital care
• Updated clinical guidelines for surgical management of Stress Urinary Incontinence
• Analysis of V2 clinical trial; superior results of quality of life improvements, sexual satisfaction scores and improved continence among PeriCoach users.
• PeriCoach patent issue for Australia.

PeriCoach is a regulated medical device, built as a data collection system. The system provides opportunity for new insights into management and motivation of the conservative treatment pathway for female pelvic floor disorders. The core capability is the driver for the pursuit of clinical evidence in the forms of studies and surveys as well as development of enhanced functionality of the PeriCoach system.

More Information

Request Information